Results 271 to 280 of about 49,482 (293)

Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma

International Journal of Radiation Oncology*Biology*Physics, 2004
The radiobiology of radioimmunotherapy is an important determinant of both the toxicity and the efficacy associated with the treatment of B-cell non-Hodgkin's lymphoma with radiolabeled anti-CD20 monoclonal antibodies. The properties of the target, CD20, and the mechanisms of action of both the monoclonal antibodies and the associated exponentially ...
M Carmen, Hernandez, Susan J, Knox
openaire   +2 more sources

Immunological evaluation of predicted linear B‐cell epitopes of human CD20 antigen

Biotechnology and Applied Biochemistry, 2012
AbstractThe importance of B‐lymphocyte‐restricted differentiation antigen Bp35 (CD20) as a target for immunotherapeutic depletion of B cells is irrefutable. Several anti‐human CD20 (anti‐hCD20) monoclonal antibodies are expressed at different stages of development.
Mahdi Habibi, Anbouhi, Mohsen, Abolhassani, Saeid, Bouzari, Hossein, Khanahmad, Mohammad Reza, Aghasadeghi, Armin, Madadkar-Sobhani, Amir, Amanzadeh, Mahdi, Behdani, Mohammad Ali, Shokrgozar   +8 more
openaire   +2 more sources

Analysis of cis-acting elements present in the CD20/B1 antigen promoter

The Journal of Immunology, 1991
Abstract A genomic clone spanning a large portion of the 5’ untranscribed region of the CD20 gene was isolated. Deletion analysis of subcloned fragments identified several regulatory elements. A major positive cis-acting element was localized between base pairs -290/-186.
P, Rieckmann, G L, Wilson, C, Thevenin, J X, Hong, J H, Kehrl   +4 more
openaire   +2 more sources

Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia

American Journal of Hematology, 1992
AbstractThe surface antigens expressed by the cells of chronic lymphocytic leukemia (CLL) are well known. Most CLL are monoclonal B‐cell lymphoproliferative disorders characterized by the coexpression of B‐cell antigens and CD5, an antigen present predominantly on T cells.
N M, Almasri, R E, Duque, J, Iturraspe, E, Everett, R C, Braylan   +4 more
openaire   +2 more sources

GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes

Leukemia Research, 2005
CD20 antigen expression in B-chronic lymphocytic leukemia (B-CLL) is at significantly lower levels than in non-Hodgkins lymphoma, which may affect the degree of anti-CD20 antibody binding. Low density of CD20 expression on malignant cells may explain the lower response rates to anti-CD20 monoclonal antibody, observed in B-CLL.
Yagci, M, Akar, I, Sucak, GT, Haznedar, R   +3 more
openaire   +3 more sources

Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody.

Journal of Clinical Oncology, 2017
e14548 Background: Chimeric Antigen Receptor T cells (CAR-Ts) targeting CD19 have shown very promising clinical outcomes in treatment of B-cell linage hematological malignancies. However, many patients with relapsed diseases were found to have down-regulated/loss of CD19 surface expression after CD19 CAR-T therapy.
Yihong Yao, Xin Yao, Shigui Zhu, Wei Zhu, Zhiyuan Li, Qingxia Wang, Lin Zhu, Anyun Ma, Yanfeng Li, Yutian Wei, Chengxiang Dai, Li Zhang, Jiaqi Huang, Bizuo Liu   +13 more
openaire   +1 more source

The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders

Expert Opinion on Biological Therapy, 2011
Immunotherapy using an antibody (rituximab) targeting CD20 antigen in combination with chemotherapy has been recently associated with significantly improved response rate and survival in patients with various types of CD20-positive B-cell lymphoproliferative disorders. This treatment may induce the disappearance of CD20 surface expression on neoplastic
Musto P, D'Auria F
openaire   +2 more sources

Effect of interferon-α on CD20 antigen expression of B–cell chronic lymphocytic leukemia

Cytokines, Cellular & Molecular Therapy, 2000
Chimeric CD20 monoclonal antibody as alternative therapy in relapsed low-grade non-Hodgkin's lymphoma (NHL) has produced responses in nearly 50% of patients. Augmenting CD20 expression on tumor cells and/or inducing its expression may increase the cell kill and effectiveness of antibody therapy. Peripheral blood lymphocytes from 19 patients with B-cell
S, Sivaraman, P, Venugopal, R, Ranganathan, C G, Deshpande, X, Huang, A, Jajeh, S A, Gregory, T, O'Brien, H D, Preisler   +8 more
openaire   +2 more sources

Development and Characterization of a New Antipeptide Monoclonal Antibody Directed to Human CD20 Antigen

Cancer Biotherapy and Radiopharmaceuticals, 2015
The rapid expansion of immunotherapeutic approaches for treatment of various diseases, including cancers, has been greatly facilitated by the invention of new generation of antibodies. Clinical studies have indicated that anti-CD20 mAb-based therapies represent an effective treatment for various diseases with overexpression of CD20 on their cell ...
Mahdi, Habibi-Anbouhi, Kayhan, Azadmanesh, Mahdi, Behdani, Ensiyeh, Hajizadeh-Saffar, Rouhollah, Vahabpour, Mohammad Ali, Shokrgozar   +5 more
openaire   +2 more sources

Construction and Characterizationc of a Camelized, Human, VH-based Peptide Vaccine Against CD20 Antigen

Immunotherapy, 2013
The purpose of this study was to construct and characterize a camelized, human, heavy-chain variable (VH) fragment-based peptide vaccine against CD20 antigen.Camelized, human VH with improved solubility and stability was used as a vaccine scaffold. A CD20 B-cell epitope was introduced into the complementarity determining region 3 of the engineered VH ...
Jianbin, Liu, Yanguo, Tan, Ranxing, Zhang   +2 more
openaire   +2 more sources